Recurrent brain tumour: the impact of illness on patient's life
- 338 Downloads
Despite advances in therapies that offer improved survival rates, clinical course of brain tumours leads to a progressive functional deterioration in patients with modifications in their psychological reaction to the disease. Patients with brain tumours are rarely assessed for quality of life and psychological variables, and even fewer studies have assessed patients who have experienced a recurrence of brain tumours. Therefore, the aim of the present study is to investigate the patients with recurrent brain tumours and their reaction to the illness.
We enrolled 81 patients with recurrent CNS tumours. Karnofsky Performance Status scale (KPS) was used to evaluate functional status of patients; the multidimensional aspect of quality of life was assessed through “Functional Assessment of Cancer Therapy-Brain” (FACT-Br), “Hospital Anxiety and Depression Scale” and “Psychological Distress Inventory”. These were all used as tests of psychological well-being.
Distress and almost all mean FACT-Br subscale scores seemed to be significantly lower in patients, in comparison with normative data. Surprisingly, the emotional well-being mean score was significantly higher in our recurrence sample than in patients with brain tumours at first diagnosis. Anxiety seemed not to be influenced by a relapse diagnosis; instead, depression was higher and differed significantly from normative data. Low correlation between KPS and FACT-Br total and some sub-scores was found.
Apparent dissociation between patients' judgment on their quality of life (bad except for emotional) and their reported distress (low) is the most intriguing finding, suggesting highly preserved coping strategies in the emotional sphere, despite intact judgment and disease awareness.
KeywordsRecurrent brain tumour Quality of life Distress Depression
Conflict of interest statement
The authors are free of professional areas of conflict of interest such as financial remuneration as employee, consultant or subcontractor with companies. The authors certify that this work was not previously sent to other journals
- 1.Associazione Italiana Registri tumori (2006) Incidence and mortality data of the Cancer Registries, 1998–2002. Brain Cancer. e&p http://www.registri-tumori.it/incidenza1998-2002/rapporto/Schede%20specifiche%20per%20tumore/Tumore%20del%20cervello.pdf
- 2.Zulch KJ (1986) Brain tumors. Their biology and pathology, 3rd edn. Springer Verlag, BerlinGoogle Scholar
- 3.Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRefGoogle Scholar
- 5.Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG, Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87PubMedCrossRefGoogle Scholar
- 6.Schiffer D (1993) Brain tumors: pathology and its biological correlates. Springer-Verlag, BerlinGoogle Scholar
- 12.Kleihues P, Cavenee WK (2000) World Health Organization classification of tumors, pathology and genetics of tumors of the nervous system. IARC press, LyonGoogle Scholar
- 16.Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer in evaluation of chemotherapeutic agents. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205, or pp. 196Google Scholar
- 24.Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B (2004) Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRefGoogle Scholar